ADVM Adverum Biotechnologies Inc

Price (delayed)

$8.15

Market cap

$169.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.2

Enterprise value

$81.58M

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ...

Highlights

The quick ratio has soared by 152% YoY and by 129% from the previous quarter

Adverum Biotechnologies's equity has surged by 118% QoQ and by 16% YoY

ADVM's gross profit has shrunk by 100% QoQ and by 100% YoY

ADVM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Sector: Healthcare

Industry: Biotechnology

Website: http://adverum.com

Peers: OMGA ONCT

Key stats

What are the main financial stats of ADVM

Market

Shares outstanding

20.76M

Market cap

$169.17M

Enterprise value

$81.58M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

0.93

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$113.99M

EBITDA

-$96.84M

Free cash flow

-$92.55M

Per share

EPS

-$10.2

Free cash flow per share

-$5.62

Book value per share

$8.78

Revenue per share

TBVPS

$16.25

Balance sheet

Total assets

$267.83M

Total liabilities

$85.54M

Debt

$63.99M

Equity

$182.29M

Working capital

$177.58M

Liquidity

Debt to equity

0.35

Current ratio

9.24

Quick ratio

9.06

Net debt/EBITDA

0.9

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-51.4%

Return on equity

-90.4%

Return on invested capital

-80.2%

Return on capital employed

-46.3%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ADVM stock price

How has the Adverum Biotechnologies stock price performed over time

Intraday

0.74%

1 week

-0.24%

1 month

16.76%

1 year

-58.63%

YTD

8.26%

QTD

18.8%

Financial performance

How have Adverum Biotechnologies's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$120.59M

Net income

-$112.9M

Gross margin

N/A

Net margin

N/A

ADVM's gross profit has shrunk by 100% QoQ and by 100% YoY

ADVM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Adverum Biotechnologies's net income has increased by 23% YoY and by 3.6% QoQ

ADVM's operating income is up by 19% YoY and by 2.7% from the previous quarter

Growth

What is Adverum Biotechnologies's growth rate over time

Valuation

What is Adverum Biotechnologies stock price valuation

P/E

N/A

P/B

0.93

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

ADVM's EPS is up by 30% YoY and by 12% QoQ

Adverum Biotechnologies's equity has surged by 118% QoQ and by 16% YoY

The price to book (P/B) is 43% lower than the 5-year quarterly average of 1.6 and 29% lower than the last 4 quarters average of 1.3

ADVM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Adverum Biotechnologies business performance

Adverum Biotechnologies's return on invested capital has shrunk by 64% YoY and by 9% QoQ

Adverum Biotechnologies's return on equity has decreased by 23% YoY but it has increased by 8% QoQ

The company's return on assets fell by 14% YoY but it rose by 2.7% QoQ

Dividends

What is ADVM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ADVM.

Financial health

How did Adverum Biotechnologies financials performed over time

ADVM's current ratio has surged by 155% year-on-year and by 124% since the previous quarter

The quick ratio has soared by 152% YoY and by 129% from the previous quarter

Adverum Biotechnologies's debt is 65% lower than its equity

Adverum Biotechnologies's equity has surged by 118% QoQ and by 16% YoY

Adverum Biotechnologies's debt to equity has shrunk by 55% QoQ and by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.